Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
April 06 2022 - 8:00AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced the
appointment of Charlene Banard to its Board of Directors. Ms.
Banard is an accomplished biopharmaceutical executive with over 30
years of experience leading global technical operations and quality
organizations within the life sciences industry. Ms. Banard will
also become a member of the company’s Audit Committee.
“Charlene is a welcome addition to AMT’s Board
of Directors, bringing critical technical operations expertise and
a strong strategic vision to the organization,” said Tahir Mahmood,
Ph.D., chief executive officer and co-founder of AMT. “We are
excited to work with Charlene, as we advance our pipeline of oral
biologic product candidates, leverage our internal GMP
manufacturing capabilities, and deepen our network of contract
development and manufacturing organization partners. With four
significant Phase 2 top-line data readouts anticipated this year,
in inflammatory bowel diseases and rheumatoid arthritis, Charlene’s
insights will be invaluable to AMT’s continued growth.”
“I am delighted to join the Board as AMT further
advances its portfolio of potentially transformational oral
biologic therapeutics,” Ms. Banard added. “The Company is well
positioned to execute on its opportunities within mucosal
immunology and beyond and I look forward to collaborating with the
entire AMT team.”
Ms. Banard is the chief technical officer of
Atara Biotherapeutics, Inc. Previously, she served as the global
head, Technical Operations, Cell & Gene Therapy Platform of
Novartis Pharmaceuticals Corporation. Prior to Novartis, Ms. Banard
was senior vice president, Global Quality, Technical Operations at
Shire Pharmaceuticals Group PLC, until it was acquired by Takeda
Pharmaceutical Company. She also served in multiple leadership
positions at Gilead Sciences, Inc., Cell Genesys, Inc., and Chiron
Corporation earlier in her career.
Ms. Banard holds a B.S. in biochemistry from
University of California at Davis and an M.B.A. in transglobal
business from Saint Mary’s College of California in Moraga.
About AMT-101AMT-101 is a novel GI-selective,
oral fusion of IL-10 and AMT’s proprietary carrier molecule,
currently in development in four Phase 2 clinical trials in
inflammatory bowel diseases and rheumatoid arthritis. AMT-101 is
designed to cross the intestinal epithelial (IE) barrier with
limited entry into the bloodstream, thereby focusing IL-10 at the
primary site of inflammation in ulcerative colitis, along the
intestinal tissue lamina propria, potentially avoiding the side
effects observed with systemic administration.
About Applied Molecular Transport
Inc.AMT is a clinical-stage biopharmaceutical company
leveraging its proprietary technology platform to design and
develop a pipeline of novel oral biologic product candidates to
treat autoimmune, inflammatory, metabolic, and other diseases.
AMT’s proprietary technology platform allows it to exploit existing
natural cellular trafficking pathways to facilitate the active
transport of diverse therapeutic modalities across the IE barrier.
Active transport is an efficient mechanism that uses the cell’s own
machinery to transport materials across the IE barrier. AMT is
developing additional oral biologic product candidates in
patient-friendly oral forms that are designed to either target
local intestinal tissue or enter systemic circulation to precisely
address the relevant pathophysiology of disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com
Forward-Looking StatementsThis
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such forward-looking
statements involve substantial risks and uncertainties. All
statements other than statements of historical facts contained in
this press release are forward-looking statements including
statements relating to AMT’s plans, expectations, forecasts and
future events. Such forward-looking statements include, but are not
limited to, the potential of, and expectations regarding AMT’s
technology platform and the extent to which it may enable the
development of new products and AMT’s internal manufacturing
capabilities, statements regarding scaling our organization,
statements regarding the potential size of the markets for our
product candidates, growth of clinical activities, or pipeline
expansion, statements regarding the optimization or expansion of
our product development plans or the design of future clinical
trials, statements regarding the potential of AMT-101, AMT-126,
AMT’s respiratory carrier technology or regarding AMT-101 and
AMT-126 clinical trials, including the timing of data readouts from
such trials, advancing product candidates to future phases of
development, and program updates, milestones for such trials, and
our ability to replicate past clinical development strategies,
statements regarding the potential for AMT’s product candidates to
treat or provide clinically meaningful outcomes for certain medical
conditions or diseases, and assumptions regarding the biological
mode of action of our product candidates and the potential to avoid
side effects with our product candidates. In some cases, you can
identify forward-looking statements by terminology such as
“believe,” “estimate,” “intend,” “may,” “plan,” “potentially,”
“will,” “expect,” “enable,” “likely” or the negative of these terms
or other similar expressions. We have based these forward-looking
statements largely on our current expectations and projections
about future events and trends that we believe may affect our
financial condition, results of operations, business strategy and
financial needs. Actual events, trends or results could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements based on various factors.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in AMT’s Annual and
Quarterly Reports on Form 10-K and 10-Q filed with the Securities
and Exchange Commission (the “SEC”), and AMT’s future reports to be
filed with the SEC. These forward-looking statements are made as of
the date of this press release, and AMT assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law.
Investor Relations Contact:Andrew ChangHead,
Investor Relations & Corporate
Communicationsachang@appliedmt.com
Media Contacts:Alexandra SantosWheelhouse Life
Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Sep 2023 to Sep 2024